ClinicalTrials.gg
RecruitingNCT06963047Updated Jun 16, 2026

Evaluation of Blood Loss After Cesarean Delivery Via US Compared to Standard Care

An interventional study of Ultrasound and Standard care in Postpartum Period, sponsored by Holy Family Hospital, Nazareth, Israel. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Holy Family Hospital, Nazareth, Israel · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Postpartum Hemorrhage with a site in Israel — 6 open to participants now, 6 under way, 1 of them phase 3. Postpartum Hemorrhage · Israel.

Planned enrollment
2nd of 12
276 · median 116
Started
2025
the only one that year
No phase
6 of 12
3 open now
Registered
9th of 12
by date
Lead sponsor
2 of 12
Holy Family Hospital, Nazareth, Israel

Among the 12 studies in Postpartum Hemorrhage with a site in Israel, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is one of 6 with no phase, and was the 9th registered.

Postpartum Hemorrhage

470 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

6 of the 12 studies in Postpartum Hemorrhage with a site in Israel are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Postpartum Hemorrhage with a site in Israel, or all of them as a file.
02

Study summary

Postpartum hemorrhage and anemia are considered a major health concern due to their impact on maternal morbidity and mortality, quality of life, and maternal cognitive and emotional functioning after delivery, which are particularly important during the critical period of mother-child bonding. Hemoglobin levels in the first 24 hours after delivery do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after delivery due to the initial redistribution of plasma volume. The aim of this study was to examine whether postpartum ultrasound examination precedes laboratory test results in the diagnosis of anemia due to blood loss after cesarean section.

Read the detailed description

According to the World Health Organization, postpartum anemia should be recognized as a major health concern, as it affects the quality of life, cognitive and emotional function of the mother, which are particularly important during the critical period of mother-child bonding. Additionally, anemia may impact mother-infant interaction, potentially leading to cognitive delays in infants. Furthermore, postpartum anemia increases the risk of postpartum depression, the need for blood transfusions, length of hospital stays, and hospitalization costs.

Hemoglobin (HB) levels within the first 24 hours postpartum do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after birth due to initial plasma volume redistribution. Diagnosis is made by measuring HB levels, and anemia is defined when HB is below 10 g at 48 hours postpartum. Postpartum anemia requires immediate treatment upon diagnosis and preferably before discharge.

The incidence of postpartum anemia in developing countries is 50-80%. This high incidence reflects a combination of reasons including under or late diagnosis, lack of awareness, and early hospital discharge.

Postpartum hemorrhage, particularly after cesarean section (CS), is a leading cause of postpartum anemia (HB \<10 g%) as well as significant morbidity and mortality. When bleeding occurs into the abdominal cavity, diagnosis is more difficult and delayed, often only detected when vital signs become unstable. Early diagnosis is crucial for proper management of blood loss and life-saving interventions. Diagnosis includes laboratory tests and imaging modalities, and treatment is determined based on severity, ranging from iron supplementation, blood transfusions, and even surgical interventions if necessary.

A certain amount of intra-abdominal fluid is common after most CS. However, there is no standardized reference in gynecological literature regarding what fluid volume is considered normal or pathological after surgery, nor its association with complications such as pain, infection, or prolonged hospitalization. Studies have shown that free intra-abdominal fluid was detected in 73% of patients after CS using CT scans, whereas ultrasound (US) detected fluid in less than 5% of women.

Recently, advanced US technology has become available, including 3D imaging and Doppler technology, which allows for quantitative fluid volume assessment. US is considered a valuable tool for rapid assessment of intra-abdominal free fluid. It is a safe, fast, and non-invasive diagnostic modality that can be used in post-cesarean women to detect and measure intra-abdominal and pelvic fluid, causing minimal patient discomfort. US has several advantages over CT scans and most gynecology departments are equipped with US machines, and gynecologists are trained to use them in clinical practice.

Currently, there is no routine use of US to assess intra-abdominal fluid volume after CS. HB levels are only measured 24 hours post-surgery, which does not necessarily reflect the nadir value. After discharge, many postpartum women may not take iron supplements due to unrecognized anemia, poor tolerance, or low adherence. The aim of this study was to examine whether postpartum ultrasound examination compared to standard care, precedes laboratory test results in the diagnosis of anemia due to blood loss after CS.

03

Conditions studied

  • Postpartum Period

Browse trials for

Keywords

  • Postpartum anemia
  • Postpartum hemorrhage
  • Ultrasound
  • Cesarean section
  • Intra-abdominal bleeding
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who delivered by a cesarean section.
  • Age over 18.
  • Fluent in Hebrew or Arabic.
  • Signed form.

Exclusion criteria

Exclusion Criteria:

  • Lack of consent or inability to provide .
  • Inability to perform a post-surgical ultrasound, such as post-surgery hospitalization in the intensive care unit.
  • Women with preoperative coagulation disorders.
  • Women whose clinical condition requires a post-cesarean ultrasound examination.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
276 participants (estimated)

Study arms

  • Active comparator
    Ultrasound group

    Group 1: patients will undergo an abdominal and transvaginal ultrasound examination within 24 - 48 hours post-surgery.

    Diagnostic Test: Ultrasound

  • Active comparator
    Standard care group

    Group 2: Candidates will be managed according to the standard care, i.e., without a routine postpartum ultrasound.

    Other: Standard care

Interventions

  • Diagnostic testUltrasound

    The purpose of the test is to diagnose and assess the amount of blood loss.

  • OtherStandard care

    Routine management

06

What researchers measure

Primary outcomes

  1. Hemoglobin drop of 2g% or more within 24 - 36 hours

    The proportion of women with a decrease in Hb levels of over 2 g% identified within 24 hours of surgery in both groups.

    Time frame: 24 -72 hours

Secondary outcomes

  1. HB levels after 48-72

    Difference in average HB levels after 48-72 hours between the two study groups

    Time frame: 72 hours postpartum

  2. Inferior Vena Cava (IVC) diameter

    Measurement of IVC diameter during inspiration and expiration

    Time frame: up to 72 hours postpartum

  3. IVC collapsibility index

    IVC expiration-IVC inspiration/IVC expiration

    Time frame: up to 72 hours postpartum

  4. Uterine walls diameter

    Measured midway between the fundus and the cervix of the uterus

    Time frame: up to 72 hours postpartum

  5. Uterine endometrial diameter

    Measuring the thickness of the inner layer of the uterus

    Time frame: up to 72 hours postpartum

  6. Uterine length

    Measured from the external cervical os to the fundus

    Time frame: up to 72 hours postpartum

  7. Maximum vertical depth of intra-abdominal fluid

    The measurement will be performed using abdominal and/or vaginal transducer

    Time frame: up to 72 hours postpartum

  8. Urine volume in the bladder

    The measurement will be performed using an abdominal or vaginal transducer

    Time frame: up to 72 hours postpartum

  9. Rate of women in the study group with intra-abdominal fluid

    The measurement will be performed using abdominal and/or vaginal transducer

    Time frame: up to 72 hours postpartum

  10. Intra-abdominal fluid volume

    The assessment will be performed using abdominal and/or vaginal transducer

    Time frame: up to 72 hours postpartum

  11. Presence of intra-abdominal hematomas

    The assessment will be performed using abdominal and/or vaginal transducer

    Time frame: up to 72 hours postpartum

  12. Objective assessment of intraoperative blood loss

    Calculated blood loss = total blood volume × (prepartum hematocrit - postpartum hematocrit) + total blood volume transfused (if applicable).

    Time frame: up to 72 hours postpartum

  13. Administration of blood products

    Number of blood units administrated

    Time frame: up to 72 hours postpartum

  14. Postoperative fever

    Maternal fever 38C or more

    Time frame: up to 72 hours postpartum

  15. Incidence of women with surgical site infection

    An infection in the part of the body where a surgery took place

    Time frame: Postoperative day 2 to day 7.

  16. Length of hospital stay

    Number of days from delivery to discharge

    Time frame: up to 10 days postpartum

  17. Maternal discomfort during the ultrasound examination

    Measured on a scale of 1 to 5 (1 = no discomfort, 5 = very uncomfortable).

    Time frame: up to 72 hours postpartum

  18. HB levels after 4 - 6 weeks

    Difference in average HB levels 4 - 6 weeks between the two study groups

    Time frame: 6 weeks postpartum

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 23 months is above that.

Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2025
First posted
May 8, 2025
StartActual
May 8, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06963047
Lead sponsor
Holy Family Hospital, Nazareth, Israel
Responsible party
Raed Salim, MD (Head of obstetrics and gynecology departement, Holy Family Hospital, Nazareth, Israel) — Principal investigator
First posted
May 8, 2025
Start date
May 8, 2025
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Raed Sa, MD
Contact
r.salim@hfhosp.org
+972544986960
Bassam Abboud, MD
Contact
Dr.bassamabb@gmail.com
+972526792999
Raed Salim, MD
study chair · Holy Family Hospital, Nazareth, Israel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion